United Kingdom

Nippon Shinyaku Co Ltd (4516.T)

4516.T on Tokyo Stock Exchange

20 Mar 2018
Change (% chg)

¥80 (+1.16%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low

Latest Key Developments (Source: Significant Developments)

Actelion wins Swiss approval of uptravi for form of high blood pressure
Tuesday, 16 Aug 2016 

Actelion Ltd : Says receives Swissmedic approval for uptravi (selexipag) for treatment of pulmonary arterial hypertension .Swissmedic has granted approval for orally active originally discovered and synthesized by Nippon Shinyaku, for patients with PAH in Switzerland.  Full Article

Nippon Shinyaku gets marketing approval of Uptravi in EU
Tuesday, 17 May 2016 

Nippon Shinyaku Co Ltd <4516.T> : Says the company obtained the marketing approval of Uptravi in EU on May 12 .Says Uptravi is a medicine for the treatment of hypertension.  Full Article